Evolus Inc
NASDAQ:EOLS
Gross Margin
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Peer Comparison
| Country | Company | Market Cap |
Gross Margin |
||
|---|---|---|---|---|---|
| US |
|
Evolus Inc
NASDAQ:EOLS
|
279.8m USD |
Loading...
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
987B USD |
Loading...
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
592.7B USD |
Loading...
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
298.4B CHF |
Loading...
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
237.8B GBP |
Loading...
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
248.3B CHF |
Loading...
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
309B USD |
Loading...
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
218B USD |
Loading...
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK |
Loading...
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
154.4B USD |
Loading...
|
|
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
124.1B USD |
Loading...
|
Market Distribution
| Min | -24 813% |
| 30th Percentile | 28.9% |
| Median | 43% |
| 70th Percentile | 60.5% |
| Max | 10 905 714.3% |
Other Profitability Ratios
Evolus Inc
Glance View
Evolus, Inc. is a medical aesthetics company, which engages in the provision of medical aesthetic treatments and procedures. The company is headquartered in Newport Beach, California and currently employs 167 full-time employees. The company went IPO on 2018-02-08. The Company’s first commercial product is Jeuveau, which is an approximately 900 kilodalton (kDa), purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Its primary market is the self-pay aesthetic market, which includes medical products purchased by physicians and other customers that are then sold to consumers or used in procedures for aesthetic indications that are not reimbursed by any third-party payor, such as Medicaid, Medicare or commercial insurance. The company offers customers and consumers a compelling value proposition with Jeuveau. BOTOX (onabotulinumtoxinA) is also an approximately 900 kDa botulinum toxin type A complex approved in the United States.
See Also
Gross Margin is calculated by dividing the Gross Profit by the Revenue.
The current Gross Margin for Evolus Inc is 65.8%, which is below its 3-year median of 68.1%.
Over the last 3 years, Evolus Inc’s Gross Margin has increased from 58.2% to 65.8%. During this period, it reached a low of 58.2% on Sep 30, 2022 and a high of 69.9% on Sep 30, 2024.
